Cumberland Pharmaceuticals Inc (CPIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $88.16M
Last updated: Nov 17, 2026 at 11:03 AM ET
Cumberland Pharmaceuticals Inc (CPIX) Earnings: Report Dates and Results
Cumberland Pharmaceuticals (CPIX) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Cumberland Pharmaceuticals reported EPS of -$0.07. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
CPIX has an expected report date of Mar 1, 2027.
CPIX Earnings Call
The latest CPIX earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 19 quarters below that had an estimate, CPIX beat 12, missed 4 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $2.16M, up 1157.1% from $171821 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2026 | $2.16M |
| Jun 30, 2026 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 4, 2026 | $166458 |
| Mar 31, 2026 | -$0.22 | N/A | N/A | N/A | N/A | -366.9% | N/A | N/A | May 5, 2026 | $9.13M |
| Dec 31, 2025 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 3, 2026 | $13.68M |
| Sep 30, 2025 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 4, 2025 | $171821 |
| Jun 30, 2025 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 5, 2025 | $380797 |
| Mar 31, 2025 | $0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 6, 2025 | $11.71M |
| Dec 31, 2024 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 4, 2025 | $10.44M |
| Sep 30, 2024 | -$0.11 | N/A | N/A | N/A | N/A | -649.5% | N/A | N/A | Nov 7, 2024 | $9.09M |
| Jun 30, 2024 | -$0.08 | N/A | N/A | N/A | N/A | -148.1% | N/A | N/A | Aug 6, 2024 | $9.85M |
| Mar 31, 2024 | -$0.14 | N/A | N/A | N/A | N/A | -225.5% | N/A | N/A | May 7, 2024 | $8.50M |
| Dec 31, 2023 | -$0.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 5, 2024 | $9.35M |
| Sep 30, 2023 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2023 | $10.09M |
| Jun 30, 2023 | $0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2023 | $10.89M |
| Mar 31, 2023 | $0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2023 | $9.22M |
| Dec 31, 2022 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 7, 2023 | $9.12M |
| Sep 30, 2022 | -$0.03 | -$0.03 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 8, 2022 | $11.41M |
| Jun 30, 2022 | -$0.09 | -$0.09 | N/A | 0.00% | In line | -212.5% | N/A | N/A | Aug 9, 2022 | $10.30M |
| Mar 31, 2022 | -$0.09 | -$0.09 | N/A | 0.00% | In line | -228.6% | N/A | N/A | May 10, 2022 | $11.18M |
| Dec 31, 2021 | -$0.26 | -$0.01 | N/A | N/A | N/A | -2700.0% | N/A | N/A | Mar 8, 2022 | $8.32M |
| Sep 30, 2021 | -$0.07 | -$0.11 | N/A | +36.36% | Beat | -450.0% | N/A | 0 up, 1 down | Nov 9, 2021 | $8.07M |
| Jun 30, 2021 | $0.08 | -$0.07 | -$0.07 - -$0.07 | +214.29% | Beat | 0.0% | 1 | N/A | Aug 10, 2021 | $9.06M |
| Mar 31, 2021 | $0.07 | -$0.07 | -$0.07 - -$0.07 | +200.00% | Beat | +600.0% | 1 | N/A | May 11, 2021 | $10.54M |
| Dec 31, 2020 | $0.01 | -$0.01 | -$0.01 - -$0.01 | +200.00% | Beat | -88.9% | 1 | N/A | Mar 9, 2021 | $10.26M |
| Sep 30, 2020 | $0.02 | -$0.07 | -$0.07 - -$0.07 | +128.57% | Beat | +100.0% | 1 | N/A | Nov 10, 2020 | $9.25M |
| Jun 30, 2020 | $0.08 | $0.03 | $0.03 - $0.03 | +166.67% | Beat | -20.0% | 1 | N/A | Aug 11, 2020 | $9.60M |
| Mar 31, 2020 | $0.01 | $0.02 | $0.02 - $0.02 | -50.00% | Miss | -90.9% | 1 | N/A | May 20, 2020 | $8.33M |
| Dec 31, 2019 | $0.09 | $0.01 | $0.01 - $0.01 | +800.00% | Beat | -10.0% | 1 | N/A | Mar 18, 2020 | $9.31M |
| Sep 30, 2019 | $0.01 | $0.11 | $0.11 - $0.11 | -90.91% | Miss | N/A | 1 | N/A | Nov 12, 2019 | $6.94M |
| Jun 30, 2019 | $0.10 | $0.07 | $0.07 - $0.07 | +42.86% | Beat | +900.0% | 1 | N/A | Aug 14, 2019 | $9.42M |
| Mar 31, 2019 | $0.11 | -$0.11 | -$0.11 - -$0.11 | +200.00% | Beat | N/A | 1 | N/A | May 14, 2019 | $8.73M |
| Dec 31, 2018 | $0.10 | -$0.16 | -$0.16 - -$0.16 | +162.50% | Beat | N/A | 1 | N/A | Feb 26, 2019 | $2.10M |
| Sep 30, 2018 | -$0.05 | -$0.19 | N/A | +73.68% | Beat | N/A | N/A | N/A | Nov 13, 2018 | $8.49M |
| Jun 30, 2018 | $0.01 | -$0.08 | -$0.08 - -$0.08 | +112.50% | Beat | N/A | 1 | N/A | Aug 14, 2018 | $10.16M |
| Mar 31, 2018 | -$0.09 | -$0.02 | -$0.02 - -$0.02 | -350.00% | Miss | -550.0% | 1 | N/A | May 8, 2018 | $8.59M |
| Dec 31, 2017 | -$0.05 | -$0.02 | N/A | -150.00% | Miss | N/A | N/A | N/A | Mar 6, 2018 | $11.65M |
| Sep 30, 2017 | -$0.05 | N/A | N/A | N/A | N/A | -881.3% | N/A | N/A | Nov 7, 2017 | $11.20M |
| Jun 30, 2017 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2017 | $8.67M |
| Mar 31, 2017 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2017 | $9.64M |
| Dec 31, 2016 | -$0.05 | N/A | N/A | N/A | N/A | -615.6% | N/A | N/A | Mar 7, 2017 | $9.08M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.19, after -$0.46 the year before. It was -$0.06 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.19 | N/A |
| Dec 31, 2024 | -$0.46 | N/A |
| Dec 31, 2023 | -$0.15 | N/A |
| Dec 31, 2022 | -$0.26 | N/A |
| Dec 31, 2021 | -$0.18 | -250.0% |
| Dec 31, 2020 | $0.12 | -61.3% |
| Dec 31, 2019 | $0.31 | N/A |
| Dec 31, 2018 | -$0.03 | N/A |
| Dec 31, 2017 | -$0.40 | N/A |
| Dec 31, 2016 | -$0.06 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,800 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 2,763 | 5 | |
| 2025Q3 | Sep 30, 2025 | 3,466 | 5 | |
| 2025Q2 | Jun 30, 2025 | 2,669 | 5 | |
| 2025Q1 | Mar 31, 2025 | 3,284 | 5 | |
| 2024Q4 | Dec 31, 2024 | 3,648 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,965 | 5 | |
| 2024Q2 | Jun 30, 2024 | 3,399 | 5 |
2026Q1 Earnings Call
Opening remarks
Emily Kent Communications, Dalton Agency Hello, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its first quarter financial results. The release also provided an overall company update, including key developments during the quarter. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. During today's call, management will share an overview of those financial results and a company update, including recent developments and a discussion of Cumberland's brands, pipeline and partners. Participating in today's call are A.J. Kazimi, Cumberland's Chief Executive Officer; Todd Anthony, Vice President, Organizational Development; and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland's annual report on Form 10-K and any subsequent updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations. So information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland's marketed brands. Full prescribing and safety information for each brand is included on the individual product website, and you can find links to those sites on the corporate site at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the financial tables of the earnings release that I noted was issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we will be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call if you prefer. With that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J. Kazimi.
A.J. Kazimi Chief Executive Officer Well, thank you, Emily, and good afternoon, everyone. We appreciate you joining us today. As Emily mentioned, we'll provide a review of our financial results for the first quarter of 2026. We'll discuss key developments during the period, but we'll also share recent updates.
Frequently Asked Questions About CPIX
When is Cumberland Pharmaceuticals's next earnings date?
Cumberland Pharmaceuticals's next earnings report is expected for Mar 1, 2027.
How often does CPIX beat earnings estimates?
Cumberland Pharmaceuticals beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +97.40%.
CPIX pages: Overview, Earnings, Financials, Valuation, Competitors